A Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176 and Multiple Doses in Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 05 Jul 2017
At a glance
- Drugs LY 3298176 (Primary) ; Dulaglutide
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly
- 28 Jun 2017 Status changed from active, no longer recruiting to completed.
- 25 May 2017 Status changed from recruiting to active, no longer recruiting.
- 20 Mar 2017 Planned End Date changed from 1 May 2017 to 15 Jun 2017.